Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Will Magenta Medical’s Elevate Disrupt the MCS Market?
Will Magenta Medical’s Elevate Disrupt the MCS Market?
Will Magenta Medical’s Elevate Disrupt the MCS Market?
Submitted by
admin
on August 8, 2024 - 10:17pm
Source:
Medical Devices and Diagnostics Industry
News Tags:
Medtech
Magenta Medical
MCS
Elevate
JNJ
Impella
Headline:
Will Magenta Medical’s Elevate Disrupt the MCS Market?
snippet:
Magenta's Elevate aims to compete with Impella by offering a smaller insertion size and higher blood flow.
The company recently raised $105 million to advance Elevate through FDA approval and clinical trials.
Results from an early feasibility study for high-risk PCI patients were showcased at the 2023 TCT conference.
Do Not Allow Advertisers to Use My Personal information